BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

Thomas J. Van Ee; Heleen H. Van Acker; Tom G. M. van Oorschot; Viggo Van Tendeloo; Evelien Smits; Ghaith Bakdash; Gerty Schreibelt; I. Jolanda M. de Vries

doi:https://doi.org/10.3390/vaccines6030065

doi.org/10.3390/vaccines6030065

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

,

,

..., I. Jolanda M. de Vries

59

Vaccines7.80

Volume: 6, Issue: 3, Pages: 65 - 65

Published: Sep 19, 2018

Abstract

Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; their presence in DC vaccines may directly hamper vaccine efficacy, whereas, in patients, BDCA1+CD14+ cells may suppress the induced immune response in...